Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice.
Adenine
/ analogs & derivatives
Adult
Aged
Aged, 80 and over
Disease Progression
Drug-Related Side Effects and Adverse Reactions
/ etiology
Female
Follow-Up Studies
Humans
Leukemia, Lymphocytic, Chronic, B-Cell
/ drug therapy
Male
Middle Aged
Piperidines
Practice Patterns, Physicians'
/ standards
Prognosis
Protein Kinase Inhibitors
/ administration & dosage
Pyrazoles
/ administration & dosage
Pyrimidines
/ administration & dosage
Retrospective Studies
Survival Rate
Withholding Treatment
/ statistics & numerical data
Chronic lymphocytic leukemia (CLL)
discontinuation
ibrutinib
progression
Journal
Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
pubmed:
25
4
2019
medline:
29
8
2020
entrez:
25
4
2019
Statut:
ppublish
Résumé
We identified all patients with chronic lymphocytic leukemia at Mayo Clinic treated with ibrutinib outside the context of a clinical trial; timing and reasons for discontinuation were ascertained, as were symptoms, exam and radiographic findings, and laboratory changes following discontinuation. Of 202 patients who received ibrutinib, 52 discontinued therapy (estimated 1- and 2-year risk of discontinuation 18% and 28%, respectively). The most common reasons for discontinuation were toxicity (56%) and progression of disease (32%, including Richter's transformation in 15%). Rapid progression of disease within 4 weeks after discontinuation was observed in 9/36 (25%) patients with adequate records for review, mostly in those stopping ibrutinib for disease progression (
Identifiants
pubmed: 31014142
doi: 10.1080/10428194.2019.1602268
pmc: PMC6813846
mid: NIHMS1028243
doi:
Substances chimiques
Piperidines
0
Protein Kinase Inhibitors
0
Pyrazoles
0
Pyrimidines
0
ibrutinib
1X70OSD4VX
Adenine
JAC85A2161
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
2712-2719Subventions
Organisme : NCI NIH HHS
ID : K12 CA090628
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA197120
Pays : United States
Commentaires et corrections
Type : CommentIn
Références
Int J Hematol. 2014 Nov;100(5):498-501
pubmed: 25034748
Case Rep Oncol. 2013 Aug 14;6(2):430-3
pubmed: 24019783
Clin Cancer Res. 2007 Sep 1;13(17):5150-5
pubmed: 17785570
Blood. 2016 Nov 3;128(18):2199-2205
pubmed: 27601462
Lancet Oncol. 2010 Oct;11(10):942-9
pubmed: 20864406
J Clin Oncol. 2013 Oct 10;31(29):e430-2
pubmed: 23752116
N Engl J Med. 2013 Jul 4;369(1):32-42
pubmed: 23782158
Haematologica. 2018 May;103(5):874-879
pubmed: 29419429
Lancet Oncol. 2018 Jan;19(1):65-75
pubmed: 29246803
Ann Oncol. 2017 May 1;28(5):1050-1056
pubmed: 28453705
J Clin Oncol. 2017 May 1;35(13):1437-1443
pubmed: 28418267
Blood. 2017 Mar 9;129(10):1270-1274
pubmed: 28096090
Blood. 2015 Mar 26;125(13):2062-7
pubmed: 25573991
JAMA Oncol. 2015 Apr;1(1):80-7
pubmed: 26182309
Cancer. 2017 Jun 15;123(12):2268-2273
pubmed: 28171709
Haematologica. 2018 Jun;103(6):e237-e240
pubmed: 29419435
Haematologica. 2016 Dec;101(12):1563-1572
pubmed: 27756834
J Thorac Oncol. 2012 Aug;7(8):e1-2
pubmed: 22797152
Am J Hematol. 2017 Dec;92(12):1362-1369
pubmed: 28940587
Haematologica. 2018 Jul;103(7):e307-e310
pubmed: 29472352
Blood Cancer J. 2014 Dec 12;4:e268
pubmed: 25501025
J Thorac Dis. 2017 Jun;9(6):E543-E546
pubmed: 28740693
Leuk Lymphoma. 2017 Jul;58(7):1630-1639
pubmed: 27885886
Blood. 2018 Jan 25;131(4):379-386
pubmed: 29255067
Am J Hematol. 2018 Aug;93(4):511-517
pubmed: 29280186